Use of a cyclic undecapeptide for the preparation of a medicament for administration during myocardial ischaemic events
The invention relates to the use of a cyclic undecapeptide, with the structure in formula (I), for the preparation of a medicament for administration during a myocardial ischaemic event.
1. A method of treating a myocardial ischemic event in an individual using a non-immunosuppressive cyclic undecapeptide having the structure of formula (I)
Formula (I)
-MeBmt-αAbu-MeAla-EtVal-Val-MeLeu-Ala-(D)Ala-MeLeu-
1 2 3 4 5 6 7 8 9
MeLeu-MeVal-
10 11
comprising administering said cyclic undecapeptide to the individual prior to and/or during reestablishment of blood flow or perfusion appropriate for an oxygen need in a heart or a cardiac tissue of said individual.
2. The method as claimed in claim 1 , wherein said myocardial ischemic event manifests itself in terms of a cardiac dysfunction.
3. The method as claimed in claim 2 , wherein said cardiac dysfunction is the consequence of cardiac cell lesions.
4. The method as claimed in claim 1 , wherein said myocardial ischemic event is encountered with a disease selected from the group consisting of: acute myocardial infarction, angina pectoris, unstable angina, atheromatous diseases with thromboembolism, vasospasms, aneurisms of the small and medium arteries and of the large vessels, arterial hypotension due to a heart or systemic disease, serious infections, severe sepsis with or without septic shock or allergic reactions, and hypotension due to the effect of one or more medicaments, drugs, poisons or toxic products.
5. The method as claimed in claim 1 , wherein the blood circulation is reestablished by means of a reperfusion obtained mechanically by coronary angioplasty and/or medically following a fibrinolysis treatment and/or following drug-based reanimation steps, and comprising administering non-immunosuppressive cyclic undecapeptide of formula (I) prior to said reperfusion.
6. The method as claimed in claim 5 , wherein the beginning of the administration of said non-immunosuppressive cyclic undecapeptide of formula (I) is spread over a period ranging from the thirtieth minute preceding the reperfusion up to the moment when the artery is reopened and/or from the reestablishment of blood flow.
7. The method as claimed in claim 6 , wherein the beginning of the administration of said non-immunosuppressive cyclic undecapeptide of formula (I) takes place in a period from, at the earliest, when the sepsis sets in and, at the latest, 72 hours.
8. The method as claimed in claim 1 , comprising administering said non-immunosuppressive cyclic undecapeptide of formula (I) at a dose ranging from 0.1 mg/kg to 30 mg/kg.
9. The method as claimed in claim 1 , comprising coadministering or administering separately said non-immunosuppressive cyclic undecapeptide of formula (I) with or from, respectively, at least a second compound that is active in anti-angina and/or anti-sepsis treatment.
10. The method as claimed in claim 1 , comprising administering said non-immunosuppressive cyclic undecapeptide of formula (I) by intravenous, intraarterial or intracoronary injection.
11. A method of treating a myocardial ischemic event in an individual using a non-immunosuppressive cyclic undecapeptide having the structure of formula (I)
Formula (I)
-MeBmt-αAbu-MeAla-EtVal-Val-MeLeu-Ala-(D)Ala-MeLeu-
1 2 3 4 5 6 7 8 9
MeLeu-MeVal-
10 11
comprising coadministering to the individual said cyclic undecapeptide and at least a second compound that is active in anti-angina and/or anti-sepsis treatment prior to and/or during reestablishment of blood flow or perfusion appropriate for an oxygen need in a heart or a cardiac tissue of said individual.
12. The method as claimed in claim 11 , wherein said myocardial ischemic event manifests itself in terms of a cardiac dysfunction.
13. The method as claimed in claim 12 , wherein said cardiac dysfunction is the consequence of cardiac cell lesions.
14. The method as claimed in claim 11 , wherein said myocardial ischemic event is encountered with a disease selected from the group consisting of: acute myocardial infarction, angina pectoris, unstable angina, atheromatous diseases with thromboembolism, vasospasms, aneurisms of the small and medium arteries and of the large vessels, arterial hypotension due to a heart or systemic disease, serious infections, severe sepsis with or without septic shock or allergic reactions, and hypotension due to the effect of one or more medicaments, drugs, poisons or toxic products.
15. The method as claimed in claim 11 , wherein the blood circulation is reestablished by means of a reperfusion obtained mechanically by coronary angioplasty and/or medically following a fibrinolysis treatment and/or following drug-based reanimation steps, and comprising administering said non-immunosuppressive cyclic undecapeptide of formula (I) prior to said reperfusion.
16. The method as claimed in claim 15 , wherein the beginning of the administration of said non-immunosuppressive cyclic undecapeptide of formula (I) is spread over a period ranging from the thirtieth minute preceding the reperfusion up to the moment when the artery is reopened and/or from the reestablishment of blood flow.
17. The method as claimed in claim 16 , wherein the beginning of the administration of said non-immunosuppressive cyclic undecapeptide of formula (I) takes place in a period from, at the earliest, when the sepsis sets in and, at the latest, 72 hours.
18. The method as claimed in claim 11 , comprising administering said non-immunosuppressive cyclic undecapeptide of formula (I) at a dose ranging from 0.1 mg/kg to 30 mg/kg.
19. The method as claimed in claim 11 , comprising administering said non-immunosuppressive cyclic undecapeptide of formula (I) by intravenous, intraarterial or intracoronary injection.